ClinicalTrials.gg
Active, not recruitingNCT07739901Updated Nov 18, 2026

Korean Real-world Study on MASLD/MASH Outcomes.

An observational study in MASLD/MASH, sponsored by Novo Nordisk A/S. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Novo Nordisk A/S · Observational

How we know

Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

This retrospective multicentre cohort study will use existing medical records from adults with Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) who underwent two Vibration-Controlled Transient Elastography-Liver Stiffness Measurement (VCTE-LSM) (FibroScan) assessments during routine clinical care. The study will evaluate whether changes in fibrosis risk tier between the two assessments are associated with future major liver-related outcomes and all-cause mortality. The duration of study will be 5 months.

02

Conditions studied

  • MASLD/MASH
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises Korean adults aged 18 years or older who received at least two VCTE examinations at participating Korean tertiary hospitals during the data period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older at the cohort entry date.
  • At least two VCTE examinations during the data period, with the interval between the first and second VCTE between 1 year and 5 years (both inclusive).
  • Diagnosis of MASLD, defined as the coexistence of hepatic steatosis confirmed by histology, imaging, or VCTE-Controlled Attenuation Parameter (CAP) more than or equal to (≥) 248 decibels per meter (dB/m), and at least one cardiometabolic criterion, in accordance with the Multi-society MASLD nomenclature consensus.

Exclusion criteria

Exclusion Criteria:

  • Prior history of hepatocellular carcinoma at any time before index date.
  • Prior history of decompensated cirrhosis (any of: bleeding oesophageal varices, ascites, hepatic encephalopathy, hepatorenal syndrome) at any time before index date.
  • Prior history of liver resection or transplantation at any time before index date.
  • Prior diagnosis of any extrahepatic at any time before index date.
  • Occurrence of any MALO component (HCC, complication of liver cirrhosis, liver transplantation, or death) within 6 months after the index date.
  • Antiviral treatment for or virus initiated more than 3 months before the index date and ongoing through the index date.
  • Total post-index follow-up duration of less than 6 months.
  • Insufficient medical record data preventing operationalisation of key study variables.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • cohort with MASLD/MASH

    Adults with MASLD/MASH who had at least two VCTE-LSM assessments performed 1 to 5 years apart during routine clinical care. Medical records will be reviewed to assess the association between changes in VCTE-LSM risk tier and long-term clinical outcomes.

    Other: No treatment is given

Interventions

  • OtherNo treatment is given

    This is a retrospective observational cohort study. The data will be collected via EMR.

06

What researchers measure

Primary outcomes

  1. Occurrence of decompensated cirrhosis

    Confirmed by referring to histology, imaging (e.g., abdominal ultrasound, computed tomography, or magnetic resonance imaging) reports. Primary endpoint will be presented with composite outcome.

    Time frame: From index date (second VCTE and start of follow-up) to the first occurrence of major adverse liver outcome (MALO) (up to 31 Dec 2025)

  2. Occurrence of hepatocellular carcinoma (HCC) confirmed by imaging or biopsy

    Confirmed by imaging or histological confirmation in the medical record. Primary endpoint will be presented with composite outcome.

    Time frame: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)

  3. Liver transplantation

    Operationalised as liver transplantation, identified by transplant procedure code or EMR documentation. Chronic liver failure not requiring transplantation is not separately ascertained and is captured within the decompensated-cirrhosis component. Primary endpoint will be presented with composite outcome.

    Time frame: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)

  4. All-cause death

    Documented in the EMR or via linkage to administrative records where available. Primary endpoint will be presented with composite outcome.

    Time frame: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Dec 28, 2026was Sep 2026
CompletionEst.
Dec 28, 2026was Sep 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 28, 2026
Nov 18, 2026
Study completion
Sep 30, 2026→Dec 28, 2026
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Sep 30, 2026→Dec 28, 2026
    Study completion Sep 30, 2026→Dec 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07739901
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Jul 13, 2026
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 28, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion